StreetInsider.com News Articles

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

Sat, 24 Oct 2026 04:15:00 -0400

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancer

Brain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient dataset

First clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC

SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

Sat, 24 Oct 2026 04:15:00 -0400

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancer

Brain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient dataset

First clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC

BeOne cancer drug combo shows 27-month median OS in gastric trial

Fri, 23 Oct 2026 10:16:24 -0400

BeOne Medicines Ltd. (NASDAQ: ONC) reported updated survival data from its Phase 3 HERIZON-GEA-01 trial, showing that a combination of Tevimbra (tislelizumab), Ziihera (zanidatamab) and chemotherapy achieved a median overall survival of 27 months in patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.

The data were presented at the European Society for Medical Oncology Congress 2026 in Madrid, Spain. The analysis was conducted after 35.3 months of median follow-up, approximately 9.4 months longer than the first interim analysis.

The three-arm trial compared Tevimbra plus Ziihera and chemotherapy, Ziihera plus chemotherapy alone, and trastuzumab plus chemotherapy as a control. Key findings include:

The

BeOne cancer drug combo shows 27-month median OS in gastric trial

Fri, 23 Oct 2026 10:16:24 -0400

The three-arm trial compared Tevimbra plus Ziihera and chemotherapy, Ziihera plus chemotherapy alone, and trastuzumab plus chemotherapy as a control. Key findings include:

The

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

Fri, 23 Oct 2026 10:15:00 -0400

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 months

TEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy

SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

Fri, 23 Oct 2026 10:15:00 -0400

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 months

TEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5

Thu, 22 Oct 2026 06:01:00 -0400

SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.

The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5

Thu, 22 Oct 2026 06:01:00 -0400

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026

Mon, 19 Oct 2026 06:00:00 -0400

New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipeline

Multiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer

SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid.

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026

Mon, 19 Oct 2026 06:00:00 -0400

Multiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer

BeOne Medicines (ONC) PT Raised to $425 at Morgan Stanley

Fri, 16 Oct 2026 08:42:14 -0400

Morgan Stanley raised its price target on BeOne Medicines (NASDAQ: ONC) to $425.00 (from $405.00) while maintaining a Overweight rating.

Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings

Fri, 16 Oct 2026 06:23:36 -0400

Investing.com -- Jefferies analysts identified their preferred mid-cap biotechnology stocks ahead of third-quarter earnings, with Oncorus (ONC) emerging as their top commercial pick, followed by Revolution Medicines (RVMD) and Alnylam Pharmaceuticals (ALNY). The firm made several price target adjustments across its coverage universe while maintaining buy ratings on select names.

The analysts noted they are closely monitoring earnings results for specific catalysts, including first revenue reports, potential earnings beats, and pipeline updates across their mid-cap biotech coverage.

1. Oncorus (ONC)

Jefferies rates the stock Buy with a $410 price target, up from $405. The firm models third-quarter Brukinsa revenue at approximately $1.36 billion

Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings

Fri, 16 Oct 2026 06:23:36 -0400

1. Oncorus (ONC)

Jefferies rates the stock Buy with a $410 price target, up from $405. The firm models third-quarter Brukinsa revenue at approximately $1.36 billion

Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings

Fri, 16 Oct 2026 06:23:36 -0400

1. Oncorus (ONC)

Jefferies rates the stock Buy with a $410 price target, up from $405. The firm models third-quarter Brukinsa revenue at approximately $1.36 billion

Form 4 BeOne Medicines Ltd. For: Oct 13 Filed by: Wang Xiaodong

Thu, 15 Oct 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20261015/27194125.html

BeOne Medicines (ONC) PT Raised to $459 at RBC Capital

Thu, 08 Oct 2026 08:27:07 -0400

RBC Capital analyst Leonid Timashev raised the price target on BeOne Medicines (NASDAQ: ONC) to $459.00 (from $450.00) while maintaining a Outperform rating.

BeOne Medicines (ONC) PT Raised to $420 at Truist Securities

Wed, 07 Oct 2026 07:13:17 -0400

Truist Securities analyst Greg Renza raised the price target on BeOne Medicines (NASDAQ: ONC) to $420.00 (from $418.00) while maintaining a Buy rating.

Form 4 BeOne Medicines Ltd. For: Sep 30 Filed by: Lee Chan Henry

Fri, 02 Oct 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20261002/27143198.html

BeOne Medicines (ONC) PT Raised to $445 at JPMorgan

Thu, 01 Oct 2026 09:06:56 -0400

JPMorgan analyst Jessica Fye raised the price target on BeOne Medicines (NASDAQ: ONC) to $445.00 (from $425.00) while maintaining a Overweight rating.

Form 4 BeOne Medicines Ltd. For: Sep 28 Filed by: Wang Xiaodong

Wed, 30 Sep 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260930/27129443.html

Form 4 BeOne Medicines Ltd. For: Sep 14 Filed by: BAKER JULIAN

Fri, 18 Sep 2026 18:47:00 -0400

si-local-file:///var/storage/secattach/20260918/27081485.html

BeOne Medicines (ONC) Reiterated at Market Outperform by Citizens on Serial Innovation

Tue, 15 Sep 2026 05:31:17 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $405.00 price target on BeOne Medicines (NASDAQ: ONC).

The analyst commented, "BeOne Medicines, Ltd. is a global oncology company with a strong commercial and R&D footprint. Its flagship product, BRUKINSA (zanubrutinib), has become the leading BTK inhibitor in the U.S., approved across five indications. The company is expanding its hematology franchise, as evidenced by its recent approval of sonrotoclax in China, and rapidly building a differentiated solid tumor pipeline. BeOne's strategy emphasizes serial innovation, deep pipeline synergy, and global market penetration. Recent events: 3Q26 U.S. approval for TEVIMBRA-based regimen for first-line

Form 4 BeOne Medicines Ltd. For: Sep 08 Filed by: Wang Xiaodong

Thu, 10 Sep 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260910/27049175.html

BeOne Medicines (ONC) PT Raised to $415 at Barclays

Thu, 10 Sep 2026 05:06:28 -0400

Barclays analyst Peter Lawson raised the price target on BeOne Medicines (NASDAQ: ONC) to $415.00 (from $407.00) while maintaining a Overweight rating.

Form 4 BeOne Medicines Ltd. For: Aug 25 Filed by: Wu Xiaobin

Thu, 27 Aug 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260827/26991170.html